Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bang K Vu

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
Dynamics of antibody domains studied by solution NMRBang K Vu, Joseph D Walsh, Dimiter S Dimitrov, et al.
Biochemical and Biophysical Research Communications|July 21, 2009
A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitorsXiaodong Xiao, Yang Feng, Bang K Vu, et al.
Acta Crystallographica. Section D, Biological Crystallography|October 22, 2008
Structure of an isolated unglycosylated antibody C(H)2 domainPonraj Prabakaran, Bang K Vu, Jianhua Gan, et al.
British Journal of Haematology|February 24, 2005
Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymeJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cellsMichaela A E Arndt, Jürgen Krauss, Bang K Vu, et al.
International Journal of Cancer|October 21, 2003
Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphomaMichaela A E Arndt, Jürgen Krauss, Robert Schwarzenbacher, et al.
Biochemical and Biophysical Research Communications|April 27, 2005
Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion proteinJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Viruses|April 3, 2021
Isolation and Characterization of Cross-Reactive Human Monoclonal Antibodies That Potently Neutralize Australian Bat Lyssavirus Variants and Other Phylogroup 1 LyssavirusesDawn L Weir, Si'Ana A Coggins, Bang K Vu, et al.
The Journal of Biological Chemistry|March 25, 2009
Engineered human antibody constant domains with increased stabilityRui Gong, Bang K Vu, Yang Feng, et al.
Journal of Immunological Methods|November 3, 2006
Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panningMei-Yun Zhang, Vidita Choudhry, Igor A Sidorov, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
Dynamics of antibody domains studied by solution NMRBang K Vu, Joseph D Walsh, Dimiter S Dimitrov, et al.
Biochemical and Biophysical Research Communications|July 21, 2009
A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitorsXiaodong Xiao, Yang Feng, Bang K Vu, et al.
Acta Crystallographica. Section D, Biological Crystallography|October 22, 2008
Structure of an isolated unglycosylated antibody C(H)2 domainPonraj Prabakaran, Bang K Vu, Jianhua Gan, et al.
British Journal of Haematology|February 24, 2005
Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymeJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cellsMichaela A E Arndt, Jürgen Krauss, Bang K Vu, et al.
International Journal of Cancer|October 21, 2003
Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphomaMichaela A E Arndt, Jürgen Krauss, Robert Schwarzenbacher, et al.
Biochemical and Biophysical Research Communications|April 27, 2005
Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion proteinJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Viruses|April 3, 2021
Isolation and Characterization of Cross-Reactive Human Monoclonal Antibodies That Potently Neutralize Australian Bat Lyssavirus Variants and Other Phylogroup 1 LyssavirusesDawn L Weir, Si'Ana A Coggins, Bang K Vu, et al.
The Journal of Biological Chemistry|March 25, 2009
Engineered human antibody constant domains with increased stabilityRui Gong, Bang K Vu, Yang Feng, et al.
Journal of Immunological Methods|November 3, 2006
Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panningMei-Yun Zhang, Vidita Choudhry, Igor A Sidorov, et al.
Pageof 2